Lemme claims that the product acts to "promote GLP-1 production," reduce hunger and cravings," "promote fat reduction and healthy weight management" on the basis of "three clinically-studied ingredients." If Lemme argues in a motion to dismiss or its Answer that the case should be barred because a private consumer cannot bring a lawsuit based on lack of adequate substantiation, the plaintiffs may argue that "clinically studied" implies "clinically proven" or "clinically shown" and, therefore, may convey that the product has the level of support touted in the advertising
References: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
This uptake leads to the downregulation of neuronal neuroligin 2 and ultimately results in synaptic alterations [153]
Here's a brief timeline: Initial Effects: Many individuals start noticing weight loss effects with tirzepatide relatively early in their treatment, but the exact timeframe can vary due to factors like dosage and individual response
Perri, M
"My fear is that there is now a belief that anyone can and should achieve a certain body shape and size with the help of these medications, so there's going to be an even greater drive towards a certain body type," said Tracy Richmond, director of the eating disorder program at Boston Children's Hospital
